Mastercard earnings set an upbeat tone for fintech stocks. These numbers stand out.
A pickup in U.S. volumes and an encouraging outlook for the year Mastercard Inc. showed a pickup in U.S. spending volumes during January, in an upbeat sign for the payments sector. The company saw U.S ...
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Eli Lilly and Company (NYSE:LLY) Lowered to Hold Rating by StockNews.com
Eli Lilly and Company (NYSE:LLY – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold ...
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Novo Nordisk's SWOT analysis: stock outlook amid GLP-1 market growth
A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...
Are weight-loss drugs like gym memberships? The answer is worth billions
An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
MM&M18h
The Escalator: Pfizer, Real Chemistry, Kailera Therapeutics and more
Archbow Consulting announced Justine Hughes has been promoted to EVP of principal operations while Honora Gabriel and Rob ...
Eli Lilly Stock's Correction Brings Opportunity
Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.